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Introduction: Guidelines caution prescribers and patients against 
chronic benzodiazepine use (BZD). Nevertheless, BZD use among 
nursing home residents remains high. We focused on individual resi-
dents and explored benefit and harm of chronic BZD use, willingness 
to try, and barriers against the discontinuation of chronic BZD use by 
questioning the general practitioner (GP) and the nurse.
Patients (or Materials) and Methods: In this cross-sectional study, 
we selected nursing home residents with at least 3 months of BZD 
use. A resident-specific questionnaire was addressed to the GP and 
nurse. For every resident, the GP and nurse had to score 8 barrier 
statements on a 10 point Likert scale. Additionally, we collected 10 
general attitudes scored by GPs and nurses. The questionnaire was 
based on an expert meeting and was pretested.
Results: We received data for 109 chronic BZD users. GPs and nurses 
indicated that the BZD still had the desired effect in, respectively, 
87% and 83% of the residents, and that except for dependence; 
there were no observed side effects in 75% and 70% of the residents. 
Overall, GPs had higher barriers than the nurses. Nevertheless, the 
willingness to stop among GPs was higher (respectively 33% vs. 
21%). Both caregivers were willing to stop in 13% of the residents. 
The most common barriers against discontinuation was for both 
caregivers the fear that initial problems will come back and the pref-
erence of a pharmacologic treatment instead of a nonpharmacologic 
treatment. The GPs perceived the resident’s motivation as a larger 
barrier than the nurses (median, 9 vs 7; P = 0.001) and indicated 
more often that discontinuation of BZDs can lead to an increase in 
care burden (median, 8 vs 6; P = 0.028). Of all 10 general statements, 
the most common attitude among both GPs and nurses was that the 
longer the resident takes the medication, the more difficult it is to stop 
(median, 8), and the resident’s old age makes it difficult and unneces-
sary to stop. Nurses, in contrast to the GPs, indicated that there is 
little knowledge on alternative strategies to handle troubles when 
stopping BZDs (median, 7 vs 2; P < 0.001) and little scientific infor-
mation available for stopping (median, 6 vs 2; P = 0.004). The scores 
for resident-specific barriers were higher than for general statements.
Conclusion: The perceived effectiveness, the absence of side effects 
and the presence of dependence in most residents that use BZD 
chronically, result in a low willingness to stop. Implementation of 
discontinuation initiatives have to address different barriers of differ-
ent parties requiring multidisciplinary evaluation of residents.
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Introduction: The ICH E7 guideline for studies involving geriatric 
patients intends to improve the knowledge about medicines in that 
population. As a legislative document, it might not reflect the needs 
of health care professionals. This study investigated what information 
health care professionals, regulatory agencies, and pharmaceutical 
industries actually consider necessary for rational drug prescribing 
to older individuals.
Patients (or Materials) and Methods: A 29-item questionnaire was 
composed, focusing on the representation of older individuals in tri-
als, the pharmacokinetics, efficacy and safety, and the convenience of 
use of medicinal products. Forty-three European physicians, pharma-
cists, ethicists, regulators, and professionals from the pharmaceuti-
cal industry, all specialized in medication for older individuals were 
included. A second questionnaire was composed of 11 control items 
and 5 new items, based on comments. Median scores, differences 
between clinical and nonclinical respondents, and the consistency of 
responses were analyzed.
Results: Thirty-seven (86%) respondents returned the initial ques-
tionnaire: 23 clinicians and 14 nonclinical professionals. The second 
was returned by 21 clinicians and 10 nonclinical professionals (31/37 
[84%]). There were no significant differences between respondents 
regarding 10 control items. Information about 32 (94%) of the 34 
items was considered necessary. Information about age-related dif-
ferences in adverse events, locomotor effects, drug–disease interac-
tions, dosing instructions, and information about the proportion of 
included 65+ patients was considered necessary by most respondents. 
The clinicians considered information significantly more important 
than did the nonclinical respondents about the inclusion of 75+, time 
until benefit in older people, anticholinergic effects, drug–disease 
interactions, and the convenience of use.
Conclusion: This study reveals that items considered necessary are 
currently not included in the ICH E7 guideline or its supplement, 
the Q&A document; namely, information about effects on the loco-
motor system, drug–disease interactions, and dosing instructions. 
Also, clinicians’ and nonclinicians’ opinions differed significantly in 
15% of the items. Therefore, all stakeholders should collaborate to 
improve the availability of information for the rational prescribing 
of medicines to older individuals.
Disclosure of Interest: E. Beers: Grant/research support from: 
Erna Beers has received a grant of the Dutch Society of Clinical 
Pharmacology & Biopharmacy (NVKF&B) for her training in clini-
cal pharmacology and therapeutics. This manuscript was written in 
the context of her training. The Expertise Centre Pharmacotherapy 
in Old Persons (EPHOR) is financially supported by The Netherlands 
Organisation for Health Research and Development (ZonMW). The 
authors’ work was independent of the NVKF&B and ZonMW. A. 
Egberts: None declared. H. Leufkens: None declared. P. Jansen: 
Grant/research support from: The Expertise Centre Pharmacotherapy 
in Old Persons (EPHOR) is financially supported by The Netherlands 
Organisation for Health Research and Development (ZonMW).
PP226—aVailable and clinically aPPlicable 
information for rational Prescribing to 
older Patients in euroPean and american 
handbooks
J.L. Boer1*; E. Beers1; T.C. Egberts2,3; H.G. Leufkens3,4; and  
P.A. Jansen1,4
1Expertise Centre Pharmacotherapy in Old Persons (EPHOR)/
Geriatric Department; 2Clinical Pharmacy, UMC Utrecht; 3Utrecht 
Institute for Pharmaceutical Sciences, Utrecht University; and 
4Dutch Medicines Evaluation Board, Utrecht, the Netherlands
Introduction: Health care professionals in daily practice use national 
handbooks for rational prescribing of medicines to older patients. 
The study objective was to investigate the availability and clinical 
applicability of such information in European and American hand-
books.
Patients (or Materials) and Methods: The Belgian Repertorium, 
German Rote Liste, British National Formulary (BNF), Dutch 
Farmacotherapeutisch Kompas (FK), and American Physician’s Desk 
Reference (Concise Monograph and Product Label [PL]) were ana-
lyzed. All 35 nongeneric medicines for diseases frequently present 
in older people with a first European centralized approval between 
2008 and 2011 and an FDA approval before October 2012 were 
included. A 19-item checklist, based on the ICH-E7 criteria, was used 
